World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301

ICV : 78.6



*Dr. Humna Sohail, Dr. Zain Nasim, Dr. Zainab Batool


Level of HbA2 more than 4% is the reliable parameter to identify ?- thalassemia carrier. However, in some cases the level is not typically increased hence leading to diagnostic dilemma. Thus the objectives of this study were to evaluate the existence of ?- thalassemia among borderline HbA2 sample of population of Faisalabad. Out of 11,790 samples received for thalassemia screening, 405 (3.4%) were found to have borderline HbA2 level. Out of this, 117(28.9%) samples were selected by simple random sampling for PCR. Multiplex ARMS-PCR was used to detect ?-globin gene mutation and multiplex gap PCR for ?-globin genes deletion. The result revealed 36 (30.8%) had ?-globin gene mutations, 8 (6.8%) had ?-globin gene deletions and 1 (0.9%) had coexistence of ? and ?-globin gene defects. The commonest gene mutation detected were CD 19 (A-G), detected from 17 (45.9%) samples, followed by 9 (24.3%) with IVS 1-1 (G-A) mutation, 5 (13.5%) with Poly A mutation and 1 (2.7%) showed CAP +1 (A-C) mutation. Two samples (5.4%) showed mutations of Poly A and CD19, 2 (5.4%) showed mutation of IVS 1-1 and CD 19 while 1 (2.7%) showed IVS 1-5 and CD 19 mutations. This study showed 10 (27.0%) positive molecular results even though the HbA2 level was at only 3.0%. There was significant number of people with HbA2 between 3.0% and 3.9% and confirmed as thalassemia carriers by PCR. This data may suggest the level of HbA2 need to be revised to ensure the success of thalassemia screening programme in our population.

[Full Text Article]

Powered By WJPMR | All Right Reserved